Table 1.
Patient characteristics by the three-item Breast Cancer Prevention Trial (BCPT) cognitive subscale scores*
| Characteristic | No. (%) | Mean (SD) BCPT cognitive subscale score | P |
|---|---|---|---|
| Insomnia† | <.001 | ||
| None (0–7) | 516 (48.13) | 0.65 (0.73) | |
| Mild (8–14) | 343 (32.00) | 1.15 (0.90) | |
| Moderate (15–21) | 167 (15.58) | 1.43 (0.84) | |
| Severe (22–28) | 46 (4.29) | 2.24 (1.14) | |
| Age, y | <.001 | ||
| >65 | 363 (33.86) | 0.80 (0.84) | |
| 55–65 | 501 (46.74) | 1.02 (0.91) | |
| <55 | 208 (19.40) | 1.32 (0.97) | |
| Race | .58 | ||
| White | 888 (82.84) | 0.99 (0.91) | |
| Non-white | 184 (17.16) | 1.04 (0.94) | |
| Education | .96 | ||
| Did not graduate college | 434 (40.52) | 1.00 (0.94) | |
| Graduated college | 637 (59.48) | 1.00 (0.90) | |
| Body mass index, kg/m2 | .24 | ||
| <25 | 416 (38.81) | 0.95 (0.89) | |
| 25–30 | 315 (29.38) | 1.00 (0.91) | |
| >30 | 341 (31.81) | 1.06 (0.95) | |
| Smoking | .36 | ||
| Never smoked | 576 (53.83) | 1.03 (0.93) | |
| Current or former smoker | 494 (46.17) | 0.97 (0.90) | |
| Alcohol | .50 | ||
| <1 drink daily | 885 (82.63) | 1.01 (0.92) | |
| ≥1 drink daily | 186 (17.37) | 0.96 (0.90) | |
| Cancer stage | .42 | ||
| 0 and I | 551 (51.98) | 1.00 (0.95) | |
| II | 370 (34.91) | 0.96 (0.85) | |
| III | 139 (13.11) | 1.08 (0.94) | |
| Years since cancer diagnoses | .97 | ||
| <2 | 473 (44.12) | 1.01 (0.90) | |
| 2–5 y | 415 (38.71) | 1.00 (0.95) | |
| >5 | 184 (17.16) | 0.99 (0.89) | |
| Chemotherapy | .002 | ||
| None | 515 (48.04) | 0.91 (0.90) | |
| Chemotherapy without taxane | 103 (9.61) | 0.99 (0.83) | |
| Taxane-based chemotherapy | 454 (42.35) | 1.11 (0.94) | |
| Radiotherapy | .10 | ||
| None | 304 (28.36) | 1.07 (0.97) | |
| Yes | 768 (71.64) | 0.97 (0.89) | |
| Surgery | .002 | ||
| Lumpectomy | 620 (57.89) | 0.93 (0.89) | |
| Mastectomy | 451 (42.11) | 1.10 (0.94) | |
| Current aromatase inhibitors (AI) | 1.00 | ||
| Anastrozole | 863 (80.88) | 1.00 (0.94) | |
| Exemestane | 57 (5.34) | 1.00 (0.78) | |
| Letrozole | 147 (13.78) | 1.00 (0.82) | |
| Years of AI use | .27 | ||
| >3 | 269 (25.09) | 0.94 (0.89) | |
| 1–3 | 546 (50.93) | 1.00 (0.93) | |
| <1 | 257 (23.97) | 1.07 (0.91) | |
| Anxiety | <.001 | ||
| No (HADS <8) | 731 (68.77) | 0.78 (0.80) | |
| Borderline (8–10) | 206 (19.38) | 1.31 (0.96) | |
| Clinically abnormal (≥11) | 126 (11.85) | 1.79 (0.91) | |
| Depression | <.001 | ||
| No (HADS <8) | 933 (88.02) | 0.89 (0.83) | |
| Borderline (8–10) | 92 (8.68) | 1.73 (0.94) | |
| Clinically Abnormal (≥11) | 35 (3.30) | 2.22 (1.22) | |
*
Variables associated with the primary outcome at P < .10 were included in the multivariable linear regression analyses (Table 2). AI = aromatase inhibitor; HADS = Hospital Anxiety and Depression Scale.
†
Insomnia Severity Index.